Appili Therapeutics' ATI-1701 vaccine shows promise in protecting against tularemia

From GlobeNewswire: 2024-10-17 07:15:33

Appili Therapeutics Inc. announced that their tularemia vaccine candidate ATI-1701 provides full protection in animal models one year after vaccination. Funding commitments from the United States Air Force Academy will advance the program towards FDA submission in 2025. Details on ATI-1701 will be presented at IDWeek 2024, highlighting the vaccine’s potential against tularemia caused by F. tularensis. The presentation is scheduled for October 17th, 2024, at the Los Angeles Convention Center. Appili is focused on developing solutions for infectious diseases, including innovative therapies to prevent severe infections and improve patient outcomes.



Read more at GlobeNewswire: Appili Therapeutics Presents Update on ATI-1701 Biodefense